10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.76%. A quarter ago, it was expected that this life science technology company would post a loss of $0.47 per share when it actually produced a loss of $0.32, delivering a surprise of 31.91%. Over the last four quarters, th ...

| --- | --- | |--------------------------------------------------------------------------|-------| | | | | | | | | | | Overview of New Chromium Product Launches | | | | | | 10x Genomics Q3 2024 Earnings – Supplemental Materials October 29, 2024 | | Introducing New Chromium Single Cell Product Families New naming convention for our products Universal Assays Universal 3' Gene Expression Formerly Single Cell Gene Expression Universal 5' Gene Expression Formerly Single Cell Immune Profiling Epi Assays Epi Multi ...

Financial Performance - Total revenue for the three months ended September 30, 2024, was $151.654 million, compared to $153.644 million for the same period in 2023, reflecting a slight decrease[18]. - Gross profit for the nine months ended September 30, 2024, was $303.527 million, up from $293.531 million in the same period of 2023, indicating a year-over-year increase of approximately 3.4%[18]. - The net loss for the three months ended September 30, 2024, was $35.753 million, compared to a net loss of $92.986 million for the same period in 2023, representing a reduction in losses of approximately 61%[18]. - Total revenue decreased by $2.0 million, or 1%, to $151.7 million for the three months ended September 30, 2024, compared to the same period in 2023[103]. - The company incurred net losses of $35.8 million for the three months ended September 30, 2024, compared to $93.0 million for the same period in 2023[101]. Cash and Liquidity - Cash and cash equivalents increased to $398.159 million as of September 30, 2024, from $359.284 million as of December 31, 2023, showing a growth of about 10.8%[15]. - As of September 30, 2024, the company had $398.2 million in cash and cash equivalents, with an accumulated deficit of $1.4 billion since inception[115]. - The net cash provided by operating activities was $13.4 million for the nine months ended September 30, 2024, compared to a net cash used of $41.0 million for the same period in 2023[123][124]. - The company expects to continue incurring operating losses for the foreseeable future but believes existing cash and cash equivalents will meet anticipated cash needs for at least the next 12 months[119]. Expenses and Liabilities - Total current liabilities decreased to $121.235 million as of September 30, 2024, from $127.162 million as of December 31, 2023, indicating a reduction of approximately 4.7%[15]. - The company reported total operating expenses of $147.878 million for the three months ended September 30, 2024, compared to $190.324 million for the same period in 2023, reflecting a decrease of approximately 22.3%[18]. - Research and development expenses for the three months ended September 30, 2024, were $66.174 million, slightly down from $66.507 million in the same period of 2023[18]. - Selling, general and administrative expenses decreased by $0.7 million, or 1%, to $81.7 million for the three months ended September 30, 2024[109]. Assets and Equity - Total assets decreased to $937.794 million as of September 30, 2024, from $965.143 million as of December 31, 2023, representing a decline of approximately 2.8%[15]. - The company’s accumulated deficit increased to $(1,418.019) million as of September 30, 2024, from $(1,284.420) million as of December 31, 2023, indicating a rise in the deficit of approximately 10.4%[15]. - As of September 30, 2023, the total stockholders' equity was $745,216,000, with a net loss of $92,986,000 for the quarter[25]. Revenue Breakdown - Total instruments revenue for the nine months ended September 30, 2024, was $68.4 million, down 19.7% from $85.1 million in the same period of 2023[53]. - Total consumables revenue increased to $359.9 million for the nine months ended September 30, 2024, up 6.1% from $339.2 million in the same period of 2023[53]. - Instruments revenue decreased by $15.9 million, or 45%, to $19.1 million for the three months ended September 30, 2024, primarily due to lower sales of Chromium and Spatial instruments[103]. - Consumables revenue increased by $11.8 million, or 10%, to $126.2 million for the three months ended September 30, 2024, driven by higher Spatial consumables sales[103]. Legal Matters - The Company was awarded over $31 million in damages from NanoString, including approximately $25 million in lost profits and $6 million in royalties[60]. - The jury found that NanoString willfully infringed the asserted patents, and the Company is seeking a permanent injunction and ongoing royalties[60]. - The Company filed a second suit against NanoString alleging infringement of U.S. Patent Nos. 10,227,639 and 11,021,737, with discovery currently in progress[61]. - The Company is involved in multiple legal actions against NanoString, including a counterclaim regarding the Company's Visium products[65]. Stock and Compensation - The weighted-average shares of common stock used in computing net loss per share, basic and diluted, were 120,733,030 for the three months ended September 30, 2024, compared to 117,728,293 for the same period in 2023[18]. - The Company reported stock-based compensation expense of $33.91 million for the three months ended September 30, 2024, compared to $40.24 million for the same period in 2023, reflecting a decrease of approximately 16.5%[86]. - The total number of shares of Class A common stock issued and outstanding as of September 30, 2024, was 106,983,035, with 14,056,833 shares of Class B common stock also outstanding[84]. Future Outlook - The company anticipates capital expenditures of approximately $15 million to $20 million over the next 12 months, focusing on manufacturing and R&D[116]. - The company regularly reviews acquisition and investment opportunities to support long-term growth objectives, which may significantly increase capital needs[118].

PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables. Began shipping GEM-X Flex, sett ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ Title of each class Trading Symbol Name of each exchange on which registered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market LLC FORM 8-K ______________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 10x Genomics, Inc. (Exact name of registrant as specified in its charter) ...

10x Genomics (TXG) is scheduled to report third-quarter 2024 results on Oct. 29, before market open. In the last reported quarter, the company's adjusted loss per share of 32 cents beat the Zacks Consensus Estimate by 31.9%. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's take a look at how things might have shaped up for GEHC prior to the announcement. Factors at Play 10x Genomics' top line is primarily driven by its two leading platforms — Visium and Zenium — in spatial bio ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Indivi ...

10x Genomics (TXG) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications. These launches are part of the company's str ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial. In my last 10x Genomics (NASDAQ: TXG ) article , I discussed how the ticker had been under relentless selling pressure, dropping from $209 in June 2021 to around $20 at the time of publication. 10x had been able to report some modest growth in He is the ...